ZVRA logo

Zevra Therapeutics (ZVRA)

Profile

Full Name

Zevra Therapeutics, Inc.

Ticker Symbol

ZVRA

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 16, 2015

Indexes

Not included

Website

http://zevra.com

Employees

59

Key Details

Price

$6.96(-0.29%)

Market cap

$376.65M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$23.61M(-14.02% YoY)

Annual EPS

-$2.28(-75.38% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$6.96
ZVRA price is $6.96

30-Day Relative Volume

1.44
ZVRA 30-day relative volume is 1.44

Price Performance

Price Most recent change

-0.29%
ZVRA price was down -0.29% on Apr 15, 2025

Price YTD change

-16.55%
ZVRA price is down -16.55% since January 1st

Price 1-year change

+45.91%
ZVRA price is up +45.91% year-on-year

Price 3-year change

+63%
ZVRA price is up +63% over the past 3 years

Price Range

Price All-time high

$418.40
ZVRA price is currently -98.34% below its historical high of $418.40

Price 3-year low

$3.89
ZVRA price is currently +78.92% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$376.65M
ZVRA market capitalization is $376.65 million

Market cap 3-year change

+156.24%
ZVRA market capitalization is up +156.24% over the past 3 years

Market cap All-time high

$517.75M
ZVRA market capitalization is currently -27.25% below its historical high of $517.75 million

Market cap sector rank

65.21%
ZVRA market capitalization is higher than 65.21% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+29.31%
ZVRA shares outstanding is up +29.31% year-on-year

Shares Outstanding 3-Year Change

+57.21%
ZVRA shares outstanding is up +57.21% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.63
ZVRA beta is 0.63

200-day SMA

$7.70
ZVRA price is currently -9.57% below its 200-day simple moving average

50-day SMA

$7.68
ZVRA price is currently -9.37% below its 50-day simple moving average

RSI

41.60
ZVRA 14-day relative strength index is 41.60

Volume

1.44
ZVRA 30-day relative volume is 1.44

ATR

$0.43
ZVRA average true range is $0.43

10-day Historical Volatility

67.06%
ZVRA 10-day historical volatility is 67.06%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$23.61M
ZVRA annual revenue is $23.61 million

Revenue Analysts estimate

$85.06M
ZVRA annual revenue is currently -72.24% lower than the consensus analysts' forecast

Revenue 1-year change

-14.02%
ZVRA annual revenue is down -14.02% year-on-year

Revenue Sector rank

35.98%
ZVRA annual revenue is higher than 35.98% of companies in Healthcare sector

EPS

EPS

-$2.28
ZVRA annual earnings per share is -$2.28

EPS Analysts estimate

$0.11
ZVRA annual earnings per share is currently -2126.67% lower than the consensus analysts' forecast

EPS 1-year change

-75.38%
ZVRA annual earnings per share is down -75.38% year-on-year

EPS Sector rank

36.29%
ZVRA annual earnings per share is higher than 36.29% of companies in Healthcare sector

Profit

Gross profit

$16.20M
ZVRA annual gross profit is $16.20 million

Gross margin

68.59%
ZVRA annual gross profit margin is 68.59%

Operating profit

-$87.00M
ZVRA annual operating income is -$87.00 million

Operating margin

-368.47%
ZVRA annual operating profit margin is -368.47%

Net income

-$105.51M
ZVRA annual net profit is -$105.51 million

Net margin

-446.85%
ZVRA annual net profit margin is -446.85%

Expenses

Total expenses

$110.61M
ZVRA annual total expenses is $110.61 million

Operating expenses

$103.20M
ZVRA annual total operating expenses is $103.20 million

Cost of goods sold

$7.42M
ZVRA annual cost of goods sold is $7.42 million

Selling, general & administrative expenses

$54.87M
ZVRA annual SGA is $54.87 million

Depreciation and amortization

$6.39M
ZVRA annual depreciation & amortization is $6.39 million

Interest expense

$7.35M
ZVRA annual interest expense is $7.35 million

Income tax

$15.37M
ZVRA annual income tax is $15.37 million

EBIT & EBITDA

EBIT

-$82.79M
ZVRA annual earnings before interest & taxes is -$82.79 million

EBITDA

-$76.55M
ZVRA annual EBITDA is -$76.55 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$178.13M
ZVRA annual total assets is $178.13 million

Non current assets

$92.10M
ZVRA annual long term assets is $92.10 million

Current assets

$86.03M
ZVRA annual total current assets is $86.03 million

Cash and cash equivalents

$33.78M
ZVRA annual cash & cash equivalents is $33.78 million

Accounts receivable

$10.18M
ZVRA annual accounts receivable is $10.18 million

Inventory

$1.97M
ZVRA annual inventory is $1.97 million

Liabilities

Total liabilities

$138.46M
ZVRA annual total liabilities is $138.46 million

Long term liabilities

$104.40M
ZVRA annual total long term liabilities is $104.40 million

Current liabilities

$34.06M
ZVRA annual total current liabilities is $34.06 million

Accounts payable

$13.07M
ZVRA annual accounts payable is $13.07 million

Debt

Total debt

$60.30M
ZVRA annual total debt is $60.30 million

Total debt 1-year change

+37.77%
ZVRA annual total debt is up +37.77% year-on-year

Long term debt

$59.88M
ZVRA annual long term debt is $59.88 million

Short term debt

$420.00K
ZVRA annual short term debt is $420.00 thousand

Equity & Capital

Shareholders equity

$39.67M
ZVRA annual stockholders equity is $39.67 million

Book value

$39.67M
ZVRA annual book value is $39.67 million

Retained earnings

-$505.29M
ZVRA annual retained earnings is -$505.29 million

Working capital

$51.96M
ZVRA annual working capital is $51.96 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$69.67M
ZVRA annual cash flow from operations is -$69.67 million

Cash from operations 1-year change

-107.74%
ZVRA annual cash flow from operations is down -107.74% year-on-year

Cash from investing

-$22.16M
ZVRA annual cash flow from investing activities is -$22.16 million

Cash from investing 1-year change

-27.44%
ZVRA annual cash flow from investing activities is down -27.44% year-on-year

Cash from financing

$82.11M
ZVRA annual cash flow from financing activities is $82.11 million

Cash from financing 1-year change

+188.46%
ZVRA annual cash flow from financing activities is up +188.46% year-on-year

CAPEX

CAPEX

-
ZVRA annual capital expenditures value is unknown

CAPEX 1-year change

-
ZVRA annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$69.67M
ZVRA annual free cash flow is -$69.67 million

Free cash flow 1-year change

-105.92%
ZVRA annual free cash flow is down -105.92% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

68.59%
ZVRA annual gross profit margin is 68.59%

Operating margin

-368.47%
ZVRA annual operating profit margin is -368.47%

Net margin

-446.85%
ZVRA annual net profit margin is -446.85%

ROA & ROE

ROA

-60.21%
ZVRA annual return on assets is -60.21%

ROE

-207.84%
ZVRA annual return on equity is -207.84%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
ZVRA price to earnings ratio value is unknown

PE ratio Sector rank

-
ZVRA price to earnings ratio is unknown

PB Ratio

PB ratio

9.50
ZVRA price to book ratio is 9.50

PB ratio Sector rank

91.6%
ZVRA price to book ratio is higher than 91.6% of companies in Healthcare sector

PS Ratio

PS ratio

15.95
ZVRA price to sales ratio is 15.95

PS ratio Sector rank

84.62%
ZVRA price to sales ratio is higher than 84.62% of companies in Healthcare sector

Enterprise value

Enterprise value

$403.16M
ZVRA enterprise value is $403.16 million

Enterprise value Sector rank

66.83%
ZVRA enterprise value is higher than 66.83% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-5.28
ZVRA EV/EBITDA is -5.28

EV/EBITDA Sector rank

18.28%
ZVRA EV/EBITDA is higher than 18.28% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.53
ZVRA annual current ratio is 2.53

Quick ratio

2.47
ZVRA annual quick ratio is 2.47

Leverage

Debt to equity

1.50
ZVRA annual debt to equity ratio is 1.50

Interest coverage ratio

-11.26
ZVRA annual interest coverage ratio is -11.26

Risk & Stability

Piotroski F-Score

2
ZVRA piotroski f-score is 2

Altman Z-Score

-3.39
ZVRA altman z-score is -3.39

Analyst ratings

Recent major analysts updates

Mar 13, 25 HC Wainwright & Co.
Buy
Mar 13, 25 Guggenheim
Buy
Mar 13, 25 Canaccord Genuity
Buy
Mar 12, 25 Citizens Capital Markets
Market Outperform
Mar 12, 25 Cantor Fitzgerald
Overweight
Nov 20, 24 HC Wainwright & Co.
Buy
Nov 14, 24 Canaccord Genuity
Buy
Oct 11, 24 Cantor Fitzgerald
Overweight
Oct 7, 24 Guggenheim
Buy
Oct 1, 24 Cantor Fitzgerald
Overweight

Institutional Ownership

Similar stocks

PACB logo
Pacific Biosciences of California (PACB)
ETON logo
Eton Pharmaceuticals (ETON)
AUTL logo
Autolus Therapeutics (AUTL)
DCTH logo
Delcath Systems (DCTH)
INNV logo
InnovAge Holding (INNV)
SANA logo
Sana Biotechnology (SANA)
CELC logo
Celcuity (CELC)
TRML logo
Tourmaline Bio (TRML)
ABVX logo
ABIVAX SA (ABVX)
  • What is the ticker symbol for Zevra Therapeutics?
  • Does Zevra Therapeutics pay dividends?
  • What sector is Zevra Therapeutics in?
  • What industry is Zevra Therapeutics in?
  • What country is Zevra Therapeutics based in?
  • When did Zevra Therapeutics go public?
  • Is Zevra Therapeutics in the S&P 500?
  • Is Zevra Therapeutics in the NASDAQ 100?
  • Is Zevra Therapeutics in the Dow Jones?
  • When was Zevra Therapeutics's last earnings report?
  • When does Zevra Therapeutics report earnings?
  • Should I buy Zevra Therapeutics stock now?

What is the ticker symbol for Zevra Therapeutics?

The ticker symbol for Zevra Therapeutics is NASDAQ:ZVRA

Does Zevra Therapeutics pay dividends?

No, Zevra Therapeutics does not pay dividends

What sector is Zevra Therapeutics in?

Zevra Therapeutics is in the Healthcare sector

What industry is Zevra Therapeutics in?

Zevra Therapeutics is in the Biotechnology industry

What country is Zevra Therapeutics based in?

Zevra Therapeutics is headquartered in United States

When did Zevra Therapeutics go public?

Zevra Therapeutics's initial public offering (IPO) was on April 16, 2015

Is Zevra Therapeutics in the S&P 500?

No, Zevra Therapeutics is not included in the S&P 500 index

Is Zevra Therapeutics in the NASDAQ 100?

No, Zevra Therapeutics is not included in the NASDAQ 100 index

Is Zevra Therapeutics in the Dow Jones?

No, Zevra Therapeutics is not included in the Dow Jones index

When was Zevra Therapeutics's last earnings report?

Zevra Therapeutics's most recent earnings report was on Mar 11, 2025

When does Zevra Therapeutics report earnings?

The next expected earnings date for Zevra Therapeutics is May 8, 2025

Should I buy Zevra Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page